ClinicalTrials.gg
CompletedNCT04933383BOREASUpdated Sep 3, 2024Results posted

Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics

A Phase 1/2 interventional study of AQ001S 0.125 mg/ml and Budesonide 0.125 mg/ml inhalation suspension in Asthma, sponsored by Aquilon Pharmaceuticals S.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-03.

Sponsored by Aquilon Pharmaceuticals S.A. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
91st of 108
23 · median 124
Started
2021
with 1 other
Phase 1/2
Only one
of the 110
Registered
101st of 110
by date

Among the 110 studies testing budesonide in Asthma, this one is the 91st largest by enrollment of the 108 interventional ones that give a count, is one of 2 that started in 2021, is the only one in phase 1/2, and was the 101st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

This is a prospective, active-controlled, randomized, open label, single-center, multiple dose, two-period crossover clinical trial to assess the efficacy, safety and pharmacokinetics of AQ001S compared to a budesonide inhalation suspension (comparator) in adults with mild asthma.

Both treatments will be administered by nebulization.

Read the detailed description

Adults patients with mild asthma (18 to 65 years old), who are 'inhaled corticosteroid (ICS)'-naïve for minimum 60 days at Screening Visit will be enrolled in the study. The patients will be treated for 28 days. The primary endpoint will be assessed by a provocative concentration of methacholine that results in a 20% drop (PC20) in the first second forced expiratory volume (FEV1) as determined by methacholine challenge test. The pharmacokinetics (PK) endpoint, i.e. PK profile of budesonide in plasma, and pharmacodynamics (PD) endpoints, i.e. recording of symptom scores, use of reliever drugs as needed, biomarkers of airway inflammation and pulmonary function tests will be assessed during the study.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18.5 and 29 kg/m2.
  • Documented clinical diagnosis of stable, persistent, asthma for at least 3 months
  • Subjects who are ICS-naïve for minimum 60 days at Screening Visit.
  • Positive methacholine (MCh) challenge test (concentration of MCh provoking an fall of 20% [PC20] \< 8 mg/ml or dose of MCh provoking an FEV1 fall of 20% [PD20] \< 0.2 mg) in the last year.
  • Post-bronchodilator FEV1 at least 80% of the predicted, documented in the last year.
  • Clinical laboratory test results, 12-lead (ECG), blood pressure and heart rate (supine) within normal reference range or judged to be not by the Investigator.
  • Female subjects of should have a negative pregnancy test at Screening Visit and use a highly effective method of .
  • Reliable subjects who are willing to be available for the duration of the clinical trial and willing to comply with clinical trial procedures.
  • Subjects who have the ability to understand the requirements of the clinical trial.
  • Subjects who have given written .

Exclusion criteria

Exclusion Criteria:

  • Current smokers or recent (\< 8 weeks) ex-smokers or ex-smokers if > 10 pack-years.
  • Pregnant or breastfeeding female subjects.
  • Inability to carry out pulmonary function testing.
  • \< 70%.
  • History of near-fatal asthma and/or intensive care unit admission for asthma symptoms.
  • Exacerbations of asthma requiring oral , hospitalization or change in asthma treatment in the previous three months.
  • Evidence of symptomatic chronic or acute respiratory infection in the previous 8 weeks.
  • Diagnosis of (COPD) or bronchiectasis.
  • Pulmonary malformations, tuberculosis, cystic fibrosis.
  • History of or existing to budesonide or any other Medicinal Product (IMP) ingredients.
  • Untreated oral candidiasis.
  • treatment, including systemic corticosteroids (e.g., oral, parenteral, ocular, nasal), within 28 days before Screening Visit.
  • Use of ICS within 60 days before Screening Visit.
  • Use of anti-leukotrienes, immunoglobulins, beta-blockers, digitalis, amiodarone, antifungals, macrolides, antidepressants, monoamine oxidase inhibitors, antiretroviral drugs, cholinesterase inhibitors, histamine, theophylline, non-steroidal anti-inflammatory drugs, anticholinergic drugs, neuroleptics, curariform drugs, antihistaminic (anti-H1) drugs, calcium channel blockers, long acting beta2-antagonists, mast cell stabilizers (e.g. natrium cromoglycate).
  • History of alcohol or drug abuse.
  • Unstable or life-threatening cardiac disease
  • History or presence of prolonged (> 470 ms), or any other abnormalities as judged by the Investigator based on 12-lead ECG recordings at Screening Visit.
  • Diabetes mellitus.
  • Neuropsychiatric diseases.
  • Clinically relevant laboratory abnormalities at Screening Visit.
  • Blood or plasma donation within 30 days prior to Screening Visit.
  • History or presence of of any system organ class (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years prior to Screening Visit, regardless of whether there is evidence of local recurrence or .
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the clinical trial.
  • History or presence of any other clinically relevant disease of any major system organ class (e.g. cardiovascular, pulmonary, renal, hepatic, gastrointestinal, reproductive, endocrinological, neurological, psychiatric or orthopedic disease) as judged by the Investigator.
  • (HIV) and severe acute respiratory syndrome (SARS)-CoV-2 infections.
  • Subjects who participated in an investigational trial within the 12 weeks prior to the start of the trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    AQ001S 0.125 mg/ml

    AQ001S 0.125 mg/ml is a budesonide inhalation solution administered by nebulization once daily.

    Drug: AQ001S 0.125 mg/ml · Drug: Budesonide 0.125 mg/ml inhalation suspension

  • Active comparator
    budesonide inhalation suspension 0.125 mg/ml

    Budesonide 0.125 mg/ml is a budesonide inhalation suspension administered by nebulization once daily.

    Drug: AQ001S 0.125 mg/ml · Drug: Budesonide 0.125 mg/ml inhalation suspension

Interventions

  • DrugAQ001S 0.125 mg/ml

    administered by nebulization once daily

    Also known as: budesonide inhalation solution 0.125 mg/ml

  • DrugBudesonide 0.125 mg/ml inhalation suspension

    Drug page: Budesonide

    administered by nebulization once daily

    Also known as: Budesonide inhalation suspension 0.125 mg/ml

06

What researchers measure

Primary outcomes

  1. Change From Baseline in PC20 After Each Treatment Period Assessed by Methacholine (MCh) Challenge Test

    At Visit 1 (baseline), Visit 2 (29-day treatment period 1) and Visit 4 (29-day treatment period 2), a MCh challenge test will be performed, i.e. up to the administration of a concentration of MCh provoking an FEV1 fall of 20% (PC20). FEV1 is measured by spirometry. The change in PC20 from baseline to the end of each period (two periods) was assessed.

    Time frame: visit 1 (baseline) - visit 2 (at the end of Treatment Period 1) and visit 4 (end of Treatment Period 2)

  2. Incidence of Treatment-Emergent Adverse Events

    Incidence of Treatment-Emergent Adverse Events as assessed by collection of (Serious) Adverse Events

    Time frame: Over the treatment period, from the informed consent signature up to the end of second 29-day treatment period

07

Results

Posted Sep 3, 2024
Limitations and caveats
No limitations or caveat are reported for this trial.

Participant flow

Cross-over part of the study (treatment period 1) - Washout period of 2 weeks - Cross-over part of the study (treatment period 2)

Participant flow — Overall Study
MilestoneSequence A: AQ001S - ComparatorSequence B: Comparator - AQ001S
Started1112
Completed1112
Not completed00

Outcome measures

PrimaryChange From Baseline in PC20 After Each Treatment Period Assessed by Methacholine (MCh) Challenge Test

At Visit 1 (baseline), Visit 2 (29-day treatment period 1) and Visit 4 (29-day treatment period 2), a MCh challenge test will be performed, i.e. up to the administration of a concentration of MCh provoking an FEV1 fall of 20% (PC20). FEV1 is measured by spirometry. The change in PC20 from baseline to the end of each period (two periods) was assessed.

Time frame:
visit 1 (baseline) - visit 2 (at the end of Treatment Period 1) and visit 4 (end of Treatment Period 2)
Reported as:
Mean · mg/mL
Change From Baseline in PC20 After Each Treatment Period Assessed by Methacholine (MCh) Challenge Test
mg/mLAQ001S 0.125 mg/mlBudesonide Inhalation Suspension 0.125 mg/ml
Change From Baseline in PC20 After Each Treatment Period Assessed by Methacholine (MCh) Challenge Test3.7 (0.9 to 6.5)1.2 (-0.7 to 3.0)
Statistical analysis
  • AQ001S 0.125 mg/ml vs Budesonide Inhalation Suspension 0.125 mg/ml · ANCOVA · p = 0.000813 · Difference/ratio of least square means: 180.6 · 95% CI 106.42 to 306.48
PrimaryIncidence of Treatment-Emergent Adverse Events

Incidence of Treatment-Emergent Adverse Events as assessed by collection of (Serious) Adverse Events

Time frame:
Over the treatment period, from the informed consent signature up to the end of second 29-day treatment period
Reported as:
Number · events
Incidence of Treatment-Emergent Adverse Events
eventsAQ001S 0.125 mg/mlBudesonide Inhalation Suspension 0.125 mg/ml
All-Cause Mortality00
Serious Adverse Events00
Other (not including serious) Adverse Events310

Adverse events

Collected over Adverse events/serious adverse events were recorded from the time the subjects signed the informed consent until the last study visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AQ001S 0.125 mg/ml0/23 (0%)0/23 (0%)4/23 (17.4%)
Budesonide Inhalation Suspension 0.125 mg/ml0/23 (0%)0/23 (0%)2/23 (8.7%)
Most frequent other events
Most frequent other events
EventAQ001S 0.125 mg/mlBudesonide Inhalation Suspension 0.125 mg/ml
Limb injuryInjury, poisoning and procedural complications1/230/23
HeadacheNervous system disorders1/231/23
ToothacheGastrointestinal disorders1/230/23
Asthmatic crisisRespiratory, thoracic and mediastinal disorders0/231/23
DyspnoeaRespiratory, thoracic and mediastinal disorders0/231/23
ArthralgiaMusculoskeletal and connective tissue disorders1/231/23
COVID-19 pneumoniaInfections and infestations1/231/23

Baseline characteristics

The efficacy population encompasses all subjects that completed both treatment periods and for which the primary efficacy parameters PC20 is available at baseline (visit 1) and after both treatment periods (visit 2 and visit 4). The safety population includes all randomized subjects who received at least one dose of the study medication (AQ001S or comparator).

Age, Categorical
Age, Categorical(Participants)Sequence A: AQ001S - ComparatorSequence B: Comparator - AQ001STotal
<=18 years000
Between 18 and 65 years111223
>=65 years000
Age, Continuous
Age, Continuous(years)Sequence A: AQ001S - ComparatorSequence B: Comparator - AQ001STotal
Mean36.3 ± 11.229.1 ± 9.932.5 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Sequence A: AQ001S - ComparatorSequence B: Comparator - AQ001STotal
Female4812
Male7411
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence A: AQ001S - ComparatorSequence B: Comparator - AQ001STotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White111223
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Sequence A: AQ001S - ComparatorSequence B: Comparator - AQ001STotal
Belgium111223
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Sequence A: AQ001S - ComparatorSequence B: Comparator - AQ001STotal
Mean24.38 ± 2.9124.24 ± 3.8624.31 ± 3.36
08

Study locations

1 site
  • Pneumocare SPRL
    Erpent, Namur 5101, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Dec 2022, 17 months.

Results were first posted in Sep 2024, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2021
First posted
Jun 21, 2021
StartActual
Jul 23, 2021
Primary completionActual
Dec 31, 2022
CompletionActual
Jan 31, 2023
Results first posted
Sep 3, 2024
Last update
Sep 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04933383
Lead sponsor
Aquilon Pharmaceuticals S.A.
Responsible party
Sponsor
First posted
Jun 21, 2021
Start date
Jul 23, 2021
Primary completion
Dec 31, 2022
Completion
Jan 31, 2023
Results posted
Sep 3, 2024
Last update
Sep 3, 2024

Study contacts

Jean-Benoît Martinot
principal investigator · Pneumocare SPRL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion